Share chart Royalty Pharma plc
Extended chart
Simple chart
About
Royalty Pharma plc - покупатель биофармацевтических лицензионных платежей и спонсор инноваций в биофармацевтической промышленности США. Он также участвует в выявлении, оценке и получении лицензионных отчислений за различные биофармацевтические препараты. Кроме того, компания сотрудничает с новаторами из академических институтов, исследовательских больниц и некоммерческих организаций, малых и средних биотехнологических компаний и фармацевтических компаний.
More detailsP/S | 8.77 |
---|---|
EV/EBITDA | 2.26 |
EBITDA | 2.64 |
Цена ао | 26.15 |
Дивиденд ао | 0.8 |
Див.доход ао | 2.73 |
P/E | 37.6 |
P/BV | 1.24 |
Число акций ао | 0.6029 млрд |
Сайт | http://www.royaltypharma.com |
Выручка | 1.81 |
ISIN | GB00BMVP7Y09 |
Валюта | usd |
IPO date | 1993-03-25 |
Sector | Health Care |
Industry | Pharmaceuticals |
Валюта отчета | usd |
Change price per day: | +1.93% (27.49) |
---|---|
Change price per week: | +0.973% (27.75) |
Change price per month: | +1.71% (27.55) |
Change price per 3 month: | +5.14% (26.65) |
Change price per half year: | +2.04% (27.46) |
Change price per year: | +2.32% (27.385) |
Change price per 3 year: | -33.27% (41.99) |
Change price per year to date: | -2.57% (28.76) |
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
Dividend, % | Dividend | Result of period | Buy before | Register closing date | Payment before |
---|---|---|---|---|---|
0.8% | 0.21 | II кв. 2024 | 14.08.2024 | 16.08.2024 | 02.09.2024 |
0.77% | 0.21 | I кв. 2024 | 14.05.2024 | 16.05.2024 | 31.05.2024 |
0.69% | 0.21 | IV кв. 2023 | 13.02.2024 | 15.02.2024 | 01.03.2024 |
0.55% | 0.2 | I кв. 2023 | 16.05.2023 | 18.05.2023 | 02.06.2023 |
0.51% | 0.2 | IV кв. 2022 | 13.02.2023 | 15.02.2023 | 02.03.2023 |
0.45% | 0.19 | III кв. 2022 | 15.11.2022 | 17.11.2022 | 02.12.2022 |
0.44% | 0.19 | II кв. 2022 | 16.08.2022 | 18.08.2022 | 02.09.2022 |
Transaction date | Date of disclosure | Insider | Type | Price | Volume | Quantity | Share before, % | Share after, % | Document |
---|---|---|---|---|---|---|---|---|---|
29.03.2023 | 30.03.2023 | Lloyd George W. EVP, Investments & CLO |
Sale | 37.03 | 473 206 | 12779 | 0 | 0 | link |
22.02.2023 | 24.02.2023 | Urist Marshall EVP, Research & Investments |
Sale | 37.3 | 870 321 | 23333 | 0 | -0.01 | link |
17.11.2022 | 21.11.2022 | RIGGS RORY B Director |
Sale | 42.33 | 5 079 600 | 120000 | 0 | -0.03 | link |
02.11.2022 | 04.11.2022 | Coyne Terrance P. EVP & CFO |
Sale | 43.06 | 236 830 | 5500 | 0 | 0 | link |
15.09.2022 | 15.09.2022 | RIGGS RORY B Director |
Sale | 42.21 | 2 195 980 | 52025 | 0 | -0.01 | link |
14.09.2022 | 15.09.2022 | RIGGS RORY B Director |
Sale | 42.41 | 2 034 620 | 47975 | 0 | -0.01 | link |
10.08.2022 | 11.08.2022 | Lloyd George W. EVP, Investments & GC |
Sale | 43.93 | 395 150 | 8995 | 0 | 0 | link |
01.08.2022 | 03.08.2022 | Coyne Terrance P. EVP & CFO |
Sale | 43.19 | 1 295 700 | 30000 | 0 | -0.01 | link |
16.05.2022 | 16.05.2022 | Urist Marshall EVP, Research & Investments |
Sale | 39.85 | 929 820 | 23333 | 0 | -0.01 | link |
29.12.2021 | 30.12.2021 | RIGGS RORY B Director |
Sale | 40 | 3 000 000 | 75000 | 0 | -0.02 | link |
28.12.2021 | 30.12.2021 | RIGGS RORY B Director |
Sale | 40.21 | 4 400 900 | 109448 | 0 | -0.03 | link |
Institutions | Volume | Share, % |
---|---|---|
Morgan Stanley | 46354266 | 10.38 |
Vanguard Group Inc | 37997522 | 8.51 |
FMR, LLC | 31583929 | 7.07 |
Blackrock Inc. | 21459462 | 4.8 |
Baillie Gifford and Company | 17590450 | 3.94 |
Adage Capital Partners GP L.L.C. | 10896931 | 2.44 |
Viking Global Investors, L.P. | 10087417 | 2.26 |
State Street Corporation | 8873550 | 1.99 |
JP Morgan Chase & Company | 8700319 | 1.95 |
Geode Capital Management, LLC | 6367611 | 1.43 |
Head | Job title | Payment | Year of birth |
---|---|---|---|
Mr. Pablo Gerardo Legorreta | Founder, Chairman of the Board & CEO | N/A | 1964 (60 years) |
Mr. Terrance P. Coyne | Executive VP & CFO | 4.35M | |
Dr. James Folmar Reddoch Ph.D. | Executive VP of Investments & Chief Scientific Officer | 3.4M | 1970 (54 years) |
Mr. George Wingate Lloyd | Executive VP of Investments & Chief Legal Officer | 4.35M | 1960 (64 years) |
Mr. Christopher Hite | Vice Chairman & Executive VP | 4.35M | 1968 (56 years) |
Ms. Kristin Stafford | Senior VP & Chief Accounting Officer | N/A | 1982 (42 years) |
Mr. Ashwin Pai M.D. | Executive Vice President of Investments | N/A | |
Dr. Marshall Jonathan Urist M.D., Ph.D. | Executive Vice President of Research & Investments | 1976 (48 years) | |
Mr. Arthur Richard McGivern J.D. | Executive Vice President of Investments & General Counsel | ||
Mr. Eric Cornelius Schneider | Senior VP & Chief Technology Officer |
Address: United States, New York, NY , 110 East 59th Street - open in Google maps, open in Yandex maps
Website: http://www.royaltypharma.com
Website: http://www.royaltypharma.com